TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors

TriSalus Life Sciences, Inc.

2024-Q1 EPS reported -$0.60 revenue$6,457,000

Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.
Operating loss Q4 $14.1M, full year $54.2M (incl. $7.9M deSPAC costs); net loss $35.5M and $59.0M.
Basic/diluted EPS loss Q4 $1.56, full year $6.73 (vs. $75.01/$161.55 in 2022, impacted by deSPAC).
Will file late 10-K due to stock-based compensation errors; results are unaudited and subject to change.
CMS granted HCPCS code for TriNav; 510k clearance for TriNav Large and TriGuide; phase 1 trials enrollment completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TriSalus Life Sciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-041538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.